Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate
Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate
Theravance Biopharma 2024年第一季度GAAP每股收益（0.24）超過預期（0.25）美元，銷售額爲1450.03萬美元，超過預期的139.63億美元
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 million which beat the analyst consensus estimate of $13.963 million by 3.87 percent. This is a 39.22 percent increase over sales of $10.417 million the same period last year.
Theravance Biopharma（納斯達克股票代碼：TBPH）公佈的季度虧損爲每股0.24美元，比分析師普遍預期的0.25美元（0.25美元）高出4％。該公司公佈的季度銷售額爲1450.3萬美元，比分析師普遍預期的1,396.3萬美元高出3.87％。這比去年同期的1041.7萬美元的銷售額增長了39.22％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。